Auranofin repurposing for lung and pancreatic cancer : low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition
Source
Journal of Experimental and Clinical Cancer Research - ISSN 1756-9966-43:1 (2024) p. 1-15
Auranofin synergizes with the PARP inhibitor olaparib to induce ROS-mediated cell death in mutant p53 cancers
Source
Antioxidants - ISSN 2076-3921-12:3 (2023) p. 1-24
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
Source
Oncoimmunology - ISSN 2162-402X-12:1 (2023) p. 1-11
Old but gold : auranofin as an innovative therapy for mutant p53 non-small cell lung cancer and pancreatic ductal adenocarcinoma
Source
Antwerpen, Universiteit Antwerpen, Faculteit Geneeskunde en Gezondheidswetenschappen, 2023,256 p.
Optimization of the solvent and in vivo administration route of auranofin in a syngeneic non-small cell lung cancer and glioblastoma mouse model
Source
Pharmaceutics - ISSN 1999-4923-14:12 (2022) p. 1-18